Clinical trials: Influenza, completed
Influenza
Phase 1 Placebo-controlled,Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Adults
The purpose of this study is to evaluate the safety and pharmacokinetics of MEDI8852 compared to placebo when administered to healthy adult subjects.
- Trial name
- MEDI8852 (NCT02350751)
- Testing
- MEDI8852
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Coronavirus Disease 2019
Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine
Popular topic：Clinical study of recombinant Novel Coronavirus vaccine (CHO cell) combined with influenza vaccine. Research purpose:Main purpose:To evaluate the immunogenicity of recombinant Novel Coronavirus vaccine (CHO cells)…
- Trial name
- NCT05107375
- Testing
- Tetravalent influenza virus lysis vaccine, Recombinant new coronavirus vaccine (CHO cell) group
- Where
- China
- Volunteers
- 299 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Pandemic Influenza
Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of Age
The present study, randomized, single-blind, dose-ranging, multicenter study, will evaluate immunogenicity, safety and tolerability of two doses of adjuvanted and not-adjuvanted new swine-origin influenza A/H1N1 virus monovalent…
- Trial name
- NCT00971100
- Testing
- Monovalent A/H1N1 influenza vaccine
- Where
- 3 sites in Belgium, Dominican Republic and 1 more
- Volunteers
- 752 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults
The purpose of this study was to determine the dose-related safety, immunogenicity, and protective efficacy of a trivalent recombinant hemagglutinin influenza vaccine in healthy adults.
- Trial name
- NCT00328107
- Testing
- Influenza Vaccine, recombinant Hemagglutinin
- Where
- 3 sites in United States
- Volunteers
- 459 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
Influenza, Whooping Cough
Assessment, Feedback, Incentive, Exchange (AFIX OB) A Customizable Quality Improvement Intervention to Increase Maternal Vaccine Uptake
The purpose of this study is to evaluate the AFIX-OB model to determine its impact on the change in flu and pertussis (Tdap) uptake, provider knowledge, attitudes and beliefs, and patient knowledge, attitudes and beliefs…
- Trial name
- AFIX-OB (NCT04678271)
- Testing
- AFIX-OB Quality Improvement Package
- Where
- United States
- Volunteers
- 202 people, healthy volunteers welcome
- Sponsor
- Yale University
Influenza
Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults
The purpose of this study is to determine if favipiravir is effective in reducing the time to resolution of influenza symptoms.
- Trial name
- NCT02008344
- Testing
- favipiravir
- Where
- 247 sites in United States, Argentina and 9 more
- Volunteers
- 1,161 people
- Sponsor
- MDVI, LLC
Influenza
Direct and Indirect Protection by Influenza Vaccine Given to Children in India
The study described here will immunize children with trivalent influenza vaccine (TIV) and determine whether this reduces influenza illness among the immunized children and their older family members.
- Trial name
- NCT00934245
- Testing
- Inactivated Trivalent Influenza Vaccine, Inactivated polio vaccine (IPV)
- Where
- India
- Volunteers
- 4,598 people, healthy volunteers welcome
- Sponsor
- Wayne Sullender, M.D.
Coccidioidomycosis
POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED)
To evaluate the safety of posaconazole (POS) in the treatment of coccidioidomycosis. Period A consisted of 2 blinded arms, posaconazole and fluconazole.
- Trial name
- NCT00423267
- Testing
- Posaconazole, Fluconazole
- Volunteers
- 16 people
- Sponsor
- Merck Sharp & Dohme LLC
Influenza A, Influenza B
Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza
Influenza (the flu) is a common illness that usually occurs in autumn and winter. The flu is usually mild, but can cause serious illness or death.
- Trial name
- NCT02287467
- Testing
- Intravenous hyperimmune immunoglobulin (IVIG)
- Where
- 21 sites in United States, Australia and 2 more
- Volunteers
- 329 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Clinical Study in Children, 6 Months to 3 Years of Age, to Assess Two Dose Levels of an Experimental Flu Vaccine, Using a Licensed Influenza Virus Vaccine, Vaxigrip® as the Control
Children younger than 5 years of age are at high risk for severe influenza disease (flu) and hospitalization due to flu. Scientists are in the process of re-evaluating the dosing initially based on whole virus vaccines to improve…
- Trial name
- NCT00778895
- Testing
- GSK Biologicals' influenza vaccine GSK1557482A, Vaxigrip
- Where
- 18 sites in Canada
- Volunteers
- 390 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Liposomal Based Intranasal Influenza Vaccine:Safety and Efficacy
Influnza vaccination is highly recommended over the age of 50,but is only 50% efficatious among the elderly. A Vaccine given as a nasal spray may improve compliance and local immunity.Liposomes are lipid particles that may serve…
- Trial name
- NCT00197301
- Testing
- Vaccination
- Where
- Israel
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Hadassah Medical Organization
Influenza
Randomized Controlled Trial of LAIV vs TIV Vaccines in Schools
Overall, this study will determine (1) the effect of vaccine type (FluMist vs. TIV) on immunization rates, (2) assess the feasibility of school immunization clinics, and (3) inform a larger study to understand the effects of…
- Trial name
- RELATIVES (NCT01995851)
- Where
- Canada
- Volunteers
- 902 people, healthy volunteers welcome
- Sponsor
- Dalhousie University
Influenza Vaccines
Immunogenicity and Safety Study of GSK Biologicals' Fluviral® (2008 - 2009 Season) in Adults Over 18 Years
This study will evaluate the immunogenicity and safety of GSK Biologicals' Trivalent split virion influenza vaccine Fluviral for the 2008-2009 season in adults over the age of 18.
- Trial name
- NCT00718120
- Testing
- Fluviral®
- Where
- Canada
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USA
The purpose of this study is to determine whether CSL425 is a safe and effective vaccine for eliciting an immune response to H1N1 influenza in healthy adults
- Trial name
- NCT00958126
- Testing
- CSL425
- Where
- 11 sites in United States
- Volunteers
- 1,313 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older
The study will evaluate the safety, tolerability and immunogenicity of different doses and types of Influenza Vaccine in healthy elderly subjects.
- Trial name
- NCT00848848
- Testing
- Trivalent Influenza Vaccine, Trivalent Influenza Vaccine + high A, Trivalent Influenza Vaccine + ¼ dose adjuvant
- Where
- Belgium
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Clinical Trial of the Inactivated Influenza Vaccine (0.25ml Formulation for Pediatric Use)
The clinical trial was designed to evaluate the immunogenicity and safety against pediatric Inactivated influenza vaccine (Split Virion) (0.25ml formulation) of Hualan administered on infants age 6 months to 36 months.
- Trial name
- NCT01554826
- Testing
- Influenza Split Vaccine, Inactivated Influenza Vaccine
- Where
- China
- Volunteers
- 810 people, healthy volunteers welcome
- Sponsor
- Hualan Biological Engineering, Inc.
Influenza Infection
Dose Sparing Intradermal S-OIV H1N1 Influenza Vaccination Device
Primary objective: To evaluate the safety and immunogenicity of low-dose ID S-OIV H1N1 vaccines delivered via a novel microneedle device (MicronJet600) and compare this to the full-dose standard IM injection.
- Trial name
- NCT01049490
- Testing
- S-OIV H1N1 vaccine
- Where
- China
- Volunteers
- 262 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Influenza, Respiratory Tract Infections
Patient Portal Reminder/Recall for Influenza Vaccination in a Health System- UCLA Portal R/R Influenza RCT 3
This trial is taking place in Los Angeles, CA among patients from primary care practices within the UCLA Health System. The study design is a 2x2x2 factorial design, nested in a parallel 2-arm trial.
- Trial name
- NCT04533685
- Testing
- Portal Reminders for Influenza Vaccination: Direct scheduling link, Portal Reminders for Influenza Vaccination: No direct scheduling link, Pre-Commitment Prompt
- Where
- United States
- Volunteers
- 213,773 people
- Sponsor
- University of California, Los Angeles
Prevention of Influenza
Demonstrate the Lot-to-lot Consistency of 3 Consecutive Batches and to Evaluate the Efficacy and Safety of GC FLU®Pre-filled Syringe Injection and 'GC FLU®Injection' Administration.
This study is aimed to confirm the lot-to-lot consistency of 3 consecutive batches of 'GC FLU® Pre-filled Syringe Injection' and 'GC FLU® Injection' in the lot-to-lot
- Trial name
- NCT02067117
- Testing
- GC FLU® Injection, GC FLU® Pre-filled Syringe Injection
- Volunteers
- 1,139 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Influenza
The Objectives of This Study Are Study of the Reactogenicity, Safety and Immunogenicity of Flu-M Inactivated Split Influenza Vaccine in Volunteers Aged 18-60 Years
Study of the Reactogenicity, Safety and Immunogenicity of Flu-M Inactivated Split Influenza Vaccine in Volunteers Aged 18-60 Years
- Trial name
- NCT05126979
- Testing
- Inactivated Split Influenza Vaccine
- Where
- Russia
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- St. Petersburg Research Institute of Vaccines and Sera
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.